@Grainofsand and @Nothofagus, BOT knows the company is on a...

@Grainofsand and @Nothofagus, BOT knows the company is on a winner just for BS, plus other 4 mature product pipelines

The detail at seven of Pfizer’s major acquisitions (Article Here).

Pfizer’s acquisition strategy in the early 2000s focused on companies with patented drugs. Its deal for Warner-Lambert and the ensuing buyout of Pharmacia in 2003 are two examples. But as healthcare costs continued to soar, the market for cheaper generic drugs showed strong potential for growth. As a result, Pfizer began targeting generic drugmakers with attractive drug pipelines, including Hospira in 2015. More recently, the company has been bolstering its pipeline of cancer treatments by acquiring several oncology-focused drug developers.

Warner-Lambert

• Type of business: pharmaceuticals
• Acquisition price: $116 billion (completed)
• Acquisition date: June 20, 2000 (completed)7

Pharmacia

• Type of business: pharmaceuticals
• Acquisition price: $60 billion (completed)
• Acquisition date: April 16, 2003 (completed)11

Wyeth

• Type of business: pharmaceuticals
• Acquisition price: $68 billion (completed)
• Acquisition date: Oct. 15, 2009 (completed)1

Hospira

• Type of business: pharmaceuticals and medical devices
• Acquisition price: $16 billion (completed)
• Acquisition date: Sept. 3, 2015 (completed)22

Medivation

• Type of business: biopharmaceuticals
• Acquisition price: $14.3 billion (completed)
• Acquisition date: Sept. 28, 2016 (completed)26

Array BioPharma

• Type of business: biopharmaceuticals
• Acquisition price: $11.2 billion (completed)
• Acquisition date: July 30, 2019 (completed)31

Trillium Therapeutics

• Type of business: biopharmaceuticals
• Acquisition price: $2.2 billion (completed)
• Acquisition date: Nov. 17, 2021 (completed)38

  
  

In addition, Pfizer's proposed acquisition of biopharmaceutical firm Global Blood Therapeutics (GBT) - announced in August 2022. GBT is the developer of Oxbryta, an FDA-approved medicine for the treatment of sickle cell disease for $5.4 billion (not completed yet)